Trial record 2 of 10 for:    Pulmonary Sarcoidosis AND NIH Clinical Center in Bethesda, Md

Eye and Immunogenetic Features of Sarcoidosis

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00379275
First received: September 20, 2006
Last updated: March 5, 2008
Last verified: December 2007
  Purpose

This study will evaluate patients with sarcoidosis to understand how the disease affects the body. Sarcoidosis is a disease that results from inflammation of body tissues. The lungs, lymph nodes in the chest, skin and eyes are most commonly affected. As the disease progresses, small lumps, or granulomas, appear in the affected tissues. In most cases, the granulomas clear up, but in cases where they do not heal and disappear, the tissues tend to remain inflamed. Eye inflammation (uveitis) associated with sarcoidosis can cause various eye diseases, sometimes leading to blindness. This study will examine the clinical, immunological and genetic features of ocular sarcoidosis.

Patients 6 years of age and older with sarcoidosis may be eligible for this study. Candidates are screened with the following procedures:

  • Completion of a questionnaire with medical, social and demographic information
  • Blood draw for laboratory tests
  • Complete eye examination, including measurement of eye pressure and dilation of the pupils to examine the back of the eye. Fluorescein angiography may be done. This test involves injecting a dye into a vein in the arm. The dye travels to the blood vessels in the eyes. A camera flashes a blue light into the eye and takes pictures of the retina that show whether the dye has leaked from the blood vessels into the retina. Other photographs of the eye may also be taken using a special camera.

Participants are followed in conjunction with their local eye doctor as required by the status of their disease. Patients whose disease is stable are seen for an initial examination and followed every 12 months for 3 years.


Condition
Sarcoidosis
Uveitis

Study Type: Observational
Official Title: Ocular and Immuno-Genetic Manifestations of Sarcoidosis

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 100
Study Start Date: September 2006
Estimated Study Completion Date: December 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

    1. Participants must be at least 6 years old
    2. Participants must have biopsy-proven sarcoidosis
    3. Participant must be able to consent to participating in the protocol
    4. For minors, consent by an adult will be necessary

EXCLUSION CRITERIA:

We will exclude participants who are unable or unwilling to give blood at the designated times in the protocol

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00379275

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00379275     History of Changes
Other Study ID Numbers: 060239, 06-EI-0239
Study First Received: September 20, 2006
Last Updated: March 5, 2008
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Sarcoidosis
Uveitis
Pulmonary Sarcoidosis
HLA-Typing
Cytokines
Serum Markers

Additional relevant MeSH terms:
Sarcoidosis
Uveitis
Chorioretinitis
Lymphoproliferative Disorders
Lymphatic Diseases
Uveal Diseases
Eye Diseases
Retinitis
Retinal Diseases
Choroiditis
Choroid Diseases
Uveitis, Posterior
Panuveitis

ClinicalTrials.gov processed this record on July 26, 2014